menu
    • menu
    [{"orgOrder":0,"company":"ProLynx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"7-Ethyl-10-Hydroxycamptothecin","moa":"DNA Topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProLynx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ProLynx \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ProLynx \/ Not Applicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Phase I","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Clovis Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Clovis Oncology \/ Not Applicable"},{"orgOrder":0,"company":"pharma&","sponsor":"Tolmar","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Rucaparib Camsylate","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"pharma&","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"pharma& \/ Tolmar","highestDevelopmentStatusID":"12","companyTruncated":"pharma& \/ Tolmar"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"J.P. Morgan Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Public Offering","leadProduct":"Rucaparib Camsylate","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clovis Oncology \/ J.P. Morgan Securities","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ J.P. Morgan Securities"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"BDR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"BDR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BDR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BDR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"US Oncology Network","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Phase III","graph3":"US Oncology Network","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"US Oncology Network \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"US Oncology Network \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Rucaparib Camsylate

    Menu

    Rucaparib Camsylate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            pharma&

                            Austria arrow
                            ELCC
                            Not Confirmed

                            pharma&

                            Austria arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rucaparib Camsylate

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Tolmar

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            pharma& Group Promotes Rubraca® For Metastatic Prostate Cancer in U.S.

                            Details : Under the terms of the Agreement, Tolmar will be responsible for U.S. marketing and sales activities to promote Rubraca (rucaparib) for BRCA-mutated Ovarian Cancer.

                            Product Name : Rubraca

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 24, 2024

                            Lead Product(s) : Rucaparib Camsylate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Tolmar

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Clovis Oncology

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Clovis Oncology

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rucaparib Camsylate

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate ...

                            Details : Rubraca(Rucaparib) is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in multiple tumor types, including ovarian and metastatic castration-resistant prostate cancers, as monotherapy, and in combination with other anti-cancer a...

                            Product Name : Rubraca

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            October 27, 2022

                            Lead Product(s) : Rucaparib Camsylate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Clovis Oncology

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Clovis Oncology

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rucaparib Camsylate

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clovis Oncology Submits Applications for Rubraca® Label Expansion in the US and European Union as First-line ...

                            Details : The ATHENA-MONO trial met its primary endpoint, showing Rubraca (rucaparib) monotherapy versus placebo improved progression-free survival (PFS) by investigator assessment in both populations in the primary efficacy analyses: HRD-positive and all patients...

                            Product Name : Rubraca

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            September 13, 2022

                            Lead Product(s) : Rucaparib Camsylate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Clovis Oncology

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Clovis Oncology

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rucaparib Camsylate,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Surviv...

                            Details : Rubraca (rucaparib) is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in multiple tumor types, including ovarian and metastatic castration-resistant prostate cancers, as monotherapy, and in combination with other anti-cancer ...

                            Product Name : Rubraca

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            September 11, 2022

                            Lead Product(s) : Rucaparib Camsylate,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Clovis Oncology

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Clovis Oncology

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rucaparib Camsylate,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Significantly Improves Progressi...

                            Details : The ATHENA-MONO trial met its primary endpoint, showing Rubraca (rucaparib) monotherapy versus placebo improved progression-free survival (PFS) by investigator assessment in both populations in the primary efficacy analyses: HRD-positive and all patients...

                            Product Name : Rubraca

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            June 06, 2022

                            Lead Product(s) : Rucaparib Camsylate,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            US Oncology Network

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            US Oncology Network

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rucaparib Camsylate,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Investigators from US Oncology Research, The US Oncology Network and Ontada Present Data Highlighting Key Adva...

                            Details : Survivorship of women with advanced ovarian cancer has improved, primarily the result of 2 key agents, bevacizumab and Poly (ADP-ribose) polymerase inhibitors. In ATHENA trial, demonstrate the efficacy and safety of a third agent Rubraca (rucaparib) for ...

                            Product Name : Rubraca

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            June 03, 2022

                            Lead Product(s) : Rucaparib Camsylate,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Clovis Oncology

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Clovis Oncology

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rucaparib Camsylate,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clovis Oncology Highlights Rubraca® (Rucaparib) and FAP-2286 Data to be Presented at 2022 ASCO Annual Meeting

                            Details : Rucaparib, an oral, small molecule inhibitor of poly (ADP-ribose) polymerase (PARP)1, 2 and 3 is being developed in multiple tumor types, including ovarian and prostate cancers, as monotherapy and in combination with other anti-cancer agents.

                            Product Name : Rubraca

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            April 28, 2022

                            Lead Product(s) : Rucaparib Camsylate,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Clovis Oncology

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Clovis Oncology

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rucaparib Camsylate

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clovis Oncology’s Rubraca® (Rucaparib) Significantly Improves Progression-Free Survival in First-line Maint...

                            Details : Rucaparib is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in multiple tumor types, including ovarian and metastatic castration-resistant prostate cancers, as monotherapy, and in combination with other anti-cancer agents.

                            Product Name : Rubraca

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            March 31, 2022

                            Lead Product(s) : Rucaparib Camsylate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            BDR Pharmaceuticals

                            India arrow
                            ELCC
                            Not Confirmed

                            BDR Pharmaceuticals

                            India arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rucaparib Camsylate

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BDR Pharma Launches the First Generic RUCAPARIB to Treat Advanced Ovarian and Prostate Cancers in India

                            Details : Rucaparib is an oral, small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP)1, 2, and 3. BDPARIB is first affordable generic in the India available in the form of a tablet, with the cost of therapy less expensive than any existing drugs in the m...

                            Product Name : Bdparib

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            May 27, 2021

                            Lead Product(s) : Rucaparib Camsylate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Clovis Oncology

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Clovis Oncology

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rucaparib Camsylate

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clovis Oncology’s Rubraca® Met The Primary Endpoint In The ARIEL4 Randomized Phase 3 Treatment Study

                            Details : The ARIEL4 study met its primary endpoint, showing a statistically significant improvement in progression-free survival for Rubraca versus chemotherapy. An expanded description of the ARIEL4 study results will be submitted for presentation at an upcoming...

                            Product Name : Rubraca

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            December 21, 2020

                            Lead Product(s) : Rucaparib Camsylate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth